RNAi-mediated inhibition of ocular hypertension targets

Details for Australian Patent Application No. 2006210451 (hide)

Owner Alcon, Inc.

Inventors Chatterton, Jon E.; Shepard, Allan R.; Clark, Abbot F.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2006210451

PCT Pub. Number WO2006/084217

Priority 60/648,926 01.02.05 US; 60/753,364 22.12.05 US

Filing date 1 February 2006

Wipo publication date 10 August 2006

Acceptance publication date 22 September 2011

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

16 August 2007 PCT application entered the National Phase

  PCT publication WO2006/084217 Priority application(s): WO2006/084217

22 September 2011 Application Accepted

  Published as AU-B-2006210451

19 January 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006210460-Antibodies that bind to EphA2 and methods of use thereof

2006210443-RNAi expression constructs